Global Blood Plasma Derivatives Market is segmented By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others), By Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrand's Disease (vWD), Other), By End-user (Hospitals, Clinics, Other)By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Blood Plasma Derivatives Market Overview
The "Global Blood Plasma Derivatives Market" is predicted to reach at a high CAGR of 4.3% during the forecast period (2022-2029)
Blood plasma is the liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes, obtained through a process known as fractionation.
Source: DataM Intelligence Analysis (2020)
Blood Plasma Derivatives Market Dynamics
Increasing prevalence of hemophilia is expected to drive the market growth
Hemophilia is an inherited bleeding disorder in which the blood doesn't clot properly due to a lack or decrease in a clotting factor protein. The most common types of hemophilia are hemophilia A, which occurs due to a lack of clotting factor VIII and hemophilia B, which is due to a lack of clotting factor IX. Either type can lead to uncontrollable bleeding into muscles, organs, and joints, as well as prolonged bleeding following injuries or surgery. The condition primarily affects males. Moreover, researchers from the Centers for Disease Control and Prevention and the U.S. HTC Network conducted a study using 2012–2018 on all male patients who attended federally supported U.S. HTCs. The study estimated the number of males with hemophilia currently living in the United States and estimated the birth rate of new cases in the United States each year. The current number of males with hemophilia living in the United States is estimated to be between 30,000 and 33,000, and the estimated prevalence of hemophilia in the United States is 12 cases per 100,000 U.S. males for hemophilia A and 3.7 cases per 100,000 U.S. males for hemophilia B.
Additionally, hemophilia prevalence differs widely across the United States. It is highest in Midwestern and Northeastern states, as the estimated incidence of hemophilia among U.S. births is one birth per 5,617 male births for hemophilia A and one birth per 19,283 male births for hemophilia B. Thus, from the above statements, the market is expected to drive in the forecast period.
High cost of plasma derivative-based therapy is expected to hamper the market growth
Plasma transfusion is most commonly used therapeutic for bleeding or in non-bleeding patients before invasive procedures or surgery. The fresh frozen plasma (FFP) method has significantly increased, leading to high healthcare costs. Although FFP is used in several clinical settings, it is often inappropriately transfused, and proof of its clinical efficacy is poor. Moreover, the total cost per unit of FFP transfused was $409·62 and $1,608·37 per patient transfused with FFP. Wasted products, in-hospital processes and overhead costs accounted for 89·8% of the total cost of FFP transfusions.
COVID-19 Impact Analysis
The new coronavirus outbreak has led to a public health emergency of international concern, putting all health organizations on high alert. During community transmission, the demand for blood and components has decreased as the health care system shifts towards treating increased numbers of COVID-19 patients, and elective surgeries and non-urgent clinical interventions are deferred. However, blood transfusions will still be necessary for emergencies such as trauma, post-partum hemorrhage, severe infant anemia, blood dyscrasias and urgent surgeries requiring blood. Although the blood component utilization rate is low in most COVID19 patients, increased stocks are needed to support COVID-19 patients with severe sepsis or those requiring extracorporeal membrane oxygenation support. Convalescent plasma, now being evaluated as a treatment for COVID-19 in some countries, requires plasma collection from recovered individuals with required minimum levels of neutralizing antibodies. Moreover, transport and trade restrictions, quarantine requirements, border control measures and production disruptions have decreased the global supply chain of critical materials and equipment used in blood and component collection and laboratory testing (including immunohematology reagents and infectious disease screening assays). The pandemic is not likely to have long-term effects on end-users primary growth in the blood plasma derivatives market.
Blood Plasma Derivatives Market Segment Analysis
Immunoglobulin segment is expected to hold the largest market share in this market segment
The immunoglobulin segment held the largest market share in 2020. Specific immunoglobulins are prepared from plasma containing high antibody levels to a certain infectious agent or antigen (such as rabies, tetanus, hepatitis B or Rh factor). For instance, according to Mayoclinic, Rabies immune globulin is given to persons exposed (e.g., by a bite, scratch, or lick) to an animal known or thought to have rabies. It is called post-exposure prophylaxis, and Rabies immune globulin is used together with rabies vaccine to prevent infection caused by the rabies virus. It works by giving the body the antibodies it needs to protect it against the rabies virus. It is called passive protection. This passive protection lasts long enough to protect the body until it can produce antibodies against the rabies virus.
Moreover, immunoglobulin is the driver for plasma procurement in most medical systems in high-income countries, and immunoglobulins made from domestic plasma are likely to have an antibody composition directed against domestic pathogens that is more suitable to treat immunodeficient patients than those made from non-domestic plasma.
Source: DataM Intelligence Analysis (2020)
Blood Plasma Derivatives Market Geographical Analysis
North America region holds the largest market share in the global blood plasma derivatives market
North America accounted for the largest market share in 2020 and expected to dominate the market over the forecast period, owing to growing awareness regarding the use and availability of plasma derivatives and high adoption of advanced technology and large players. For instance, according to the World Health Organization, awareness of the value of plasma for the manufacture of Plasma-derived medicinal products (PDMPs) and a responsibility to avoid the competent health authority establishes wastage of plasma that could be fractionated as part of the national blood policy. Moreover, supplying plasma to a fractionator can provide an economic return on the cost of investment in quality. Income from supplying plasma can enable blood organizations to achieve their mission of providing an adequate supply of safe blood products for transfusion through the funding of critical operations, enhancing blood center sustainability. The awareness of policy-makers is enhanced on the role of human plasma both for clinical use and particularly as a raw material for the fractionation and manufacture of PDMPs.
Source: DataM Intelligence Analysis (2020)
Blood Plasma Derivatives Market Competitive Landscape
The blood plasma derivatives market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Grifols, S.A., SK Plasma Co., Ltd., Fusion Health Care Pvt. Ltd., Biotest AG, Green Cross Corporation, Baxter International Inc., LFB S.A., Octapharma AG, CSL Limited and Shire Plc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood plasma derivatives market globally.
Blood Plasma Derivatives Market Key Companies to Watch
SK Plasma Co., Ltd.:
Overview:
SK Plasma Co., Ltd., established in 1970, is one of the biological medicine companies in SK Group. It has been developing and manufacturing high-quality plasma-derived medicines and is expanding into new areas of unmet need globally, utilizing a new fractionation facility established in 2018. Moreover, the company is open to business models such as intermediates, finished products, toll-manufacturing and tech-transfer, etc. SK Plasma also offer various services upgrading collection centers and toll-manufacturing to many countries and regions, receiving locally collected plasma and returning derivative products.
Product Portfolio:
SK Plasma Co., Ltd. has continuously set new standards for manufacturing and distributing plasma derived products worldwide, such as Albumin, Immunoglobulin G, Factor VIII, etc.
Why Purchase the Report?
- Visualize the composition of the blood plasma derivatives market segmentation by type, application, end user and region highlighting the key commercial assets and players.
- Identify commercial opportunities in blood plasma derivatives market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of blood plasma derivatives market- level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global blood plasma derivatives market report would provide an access to an approx.55 market data table, 55 figures and 180pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
